Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position Paper
Authors:
- 30 January 2024
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 78 (1) , 153-165
Abstract
The broad spectrum of hepatobiliary involvement in cystic fibrosis (CF) has been commonly referred to as cystic fibrosis liver disease (CFLD). However, differences in the definitions of CFLD have led to variations in reported prevalence, incidence rates, and standardized recommendations for diagnosis and therapies.Harmonizing the description of the spectrum of hepatobiliary involvement in all people with CF (pwCF) is deemed essential for providing a reliable account of the natural history, which in turn supports the development of meaningful clinical outcomes in patient care and research.Recognizing this necessity, The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) commissioned and tasked a committee to develop and propose a systematic classification of the CF hepatobiliary manifestations to increase uniformity, accuracy, and comparability for clinical, registry, and research purposes. This report describes the committee's combined expert position statement on hepatobiliary involvement in CF, which has been endorsed by NASPGHAN and ESPGHAN.We recommend using CFHBI (Cystic Fibrosis Hepato‐Biliary Involvement) as the updated term to describe and classify all hepatobiliary manifestations in all pwCF. CFHBI encompasses the current extensive spectrum of phenotypical, clinical, or diagnostic expressions of liver involvement observed in pwCF. We present a schematic categorization of CFHBI, which may also be used to track and classify the changes and development of CFHBI in pwCF over time. The proposed classification for CFHBI is based on expert consensus and has not been validated for clinical practice and research purposes. Achieving validation should be an important aim for future research.Keywords
This publication has 103 references indexed in Scilit:
- Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosisJournal of Cystic Fibrosis, 2013
- Magnetic resonance elastography of liver: Technique, analysis, and clinical applicationsJournal of Magnetic Resonance Imaging, 2013
- Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United StatesJNCI: Journal of the National Cancer Institute, 2012
- Non-Invasive Evaluation of Cystic Fibrosis Related Liver Disease in Adults with ARFI, Transient Elastography and Different Fibrosis ScoresPLOS ONE, 2012
- Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsyHepatology, 2010
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factorsThe Journal of Pediatrics, 2003
- Liver function and morphology during long‐term fatty acid supplementation in cystic fibrosisLiver International, 1994
- Liver Disease and Common-Bile-Duct Stenosis in Cystic FibrosisNew England Journal of Medicine, 1988
- Cystic fibrosis with extensive fat replacement of the liverThe Journal of Pediatrics, 1966